Equillium Announces Leadership and Corporate Updates
Equillium (Nasdaq: EQ) announced leadership and corporate governance updates effective October 1, 2025, and a contract termination dated September 30, 2025. Stephen Connelly, Ph.D. was promoted to President while retaining his Chief Scientific Officer role. Daniel M. Bradbury moved from Executive Chairman to Chairman of the Board, and Bruce Steel remains CEO and a board member. Both Stephen Connelly and Bala Manian tendered resignations from the board, stated as not resulting from any disagreement with the company. Separately, Equillium and Biocon agreed to terminate their collaboration and license arrangements related to itolizumab.
Company commentary emphasized a sharpened pipeline focus on advancing EQ504 into the clinic and improving capital efficiency.
Equillium (Nasdaq: EQ) ha annunciato aggiornamenti alla leadership e alla governance aziendale efficaci dal 1° ottobre 2025, e una terminazione contrattuale datata 30 settembre 2025. Stephen Connelly, Ph.D. è stato promosso a Presidente mantenendo il ruolo di Chief Scientific Officer. Daniel M. Bradbury è passato da Executive Chairman a Chairman del Consiglio, e Bruce Steel resta CEO e membro del consiglio. Sia Stephen Connelly che Bala Manian hanno rassegnato le loro dimissioni dal consiglio, dichiarando che non derivano da alcun dissenso con l'azienda. Separatamente, Equillium e Biocon hanno concordato di terminare la loro collaborazione e gli accordi di licenza correlati a itolizumab.
Il commento dell'azienda ha enfatizzato un focus più acuto sul portafoglio progetti per avanzare EQ504 in clinica e migliorare l'efficienza del capitale.
Equillium (Nasdaq: EQ) anunció actualizaciones de liderazgo y gobernanza corporativa vigentes a partir del 1 de octubre de 2025, y una terminación de contrato fechada el 30 de septiembre de 2025. Stephen Connelly, Ph.D. fue promovido a Presidente mientras mantiene su cargo de Chief Scientific Officer. Daniel M. Bradbury pasó de Chairman Ejecutivo a Chairman de la Junta, y Bruce Steel continúa como CEO y miembro de la junta. Tanto Stephen Connelly como Bala Manian presentaron su renuncia a la junta, indicándose que no proviene de ningún desacuerdo con la empresa. Por separado, Equillium y Biocon acordaron terminar su colaboración y los acuerdos de licencia relacionados con itolizumab.
El comentario de la empresa enfatizó un enfoque más nítido en el pipeline para avanzar EQ504 hacia la clínica y mejorar la eficiencia de capital.
Equillium (나스닥: EQ)가 2025년 10월 1일부터 발효되는 리더십 및 기업 거버넌스 업데이트를 발표했고, 2025년 9월 30일자로 계약 해지를 발표했습니다. Stephen Connelly, Ph.D.가 최고과학책임자(CSO) 직위를 유지하며 사장으로 승진했습니다. Daniel M. Bradbury는 Executive Chairman에서 이사회 의장으로 이동했고, Bruce Steel은 CEO이자 이사로 남습니다. Stephen Connelly와 Bala Manian은 이사회에서 물러났으며, 회사와의 어떠한 이견도 원인이 아니라고 밝혔습니다. Separately, Equillium과 Biocon은 itolizumab와 관련된 협력 및 라이선스 계약을 종료하기로 합의했습니다.
회사 논평은 EQ504를 임상으로 추진하고 자본 효율성을 높이는 데 초점을 맞춘 파이프라인 강화에 초점을 맞췄다고 강조했습니다.
Equillium (Nasdaq: EQ) a annoncé des mises à jour de la direction et de la gouvernance d'entreprise, effectives à partir du 1er octobre 2025, et une résiliation de contrat datée du 30 septembre 2025. Stephen Connelly, Ph.D. a été promu Président tout en conservant son rôle de Chief Scientific Officer. Daniel M. Bradbury est passé de Chairman Exécutif à Chairman du Conseil, et Bruce Steel demeure CEO et membre du conseil. Stephen Connelly et Bala Manian ont tous deux présenté leur démission du conseil, déclarant que cela ne résulte d’aucun désaccord avec l’entreprise. Par ailleurs, Equillium et Biocon ont convenu de mettre fin à leur collaboration et aux accords de licence relatifs à itolizumab.
Les commentaires de l’entreprise ont souligné un accent accru sur le pipeline pour faire avancer EQ504 en clinique et améliorer l’efficacité du capital.
Equillium (Nasdaq: EQ) gab Updates zur Führung und Unternehmensführung bekannt, die am 1. Oktober 2025 in Kraft treten, sowie eine vertragliche Beendigung mit Datum 30. September 2025. Stephen Connelly, Ph.D. wurde zum Präsidenten befördert, behält aber seine Rolle als Chief Scientific Officer. Daniel M. Bradbury wechselte vom Executive Chairman zum Vorsitzenden des Vorstands, und Bruce Steel bleibt CEO und Mitglied des Vorstands. Sowohl Stephen Connelly als auch Bala Manian legten ihren Rücktritt aus dem Vorstand ein und erklärten, dass dies nicht aufgrund von Meinungsverschiedenheiten mit dem Unternehmen erfolgte. Separat einigten sich Equillium und Biocon darauf, ihre Zusammenarbeit und die damit verbundenen Lizenzvereinbarungen im Zusammenhang mit Itolizumab zu beenden.
Das Unternehmensstatement hob einen schärferen Fokus auf die Pipeline hervor, um EQ504 in die Klinik zu bringen und die Kapitalproduktivität zu verbessern.
Equillium (بورصة ناسداك: EQ) أعلنت عن تحديثات في القيادة وحوكمة الشركة سارية اعتباراً من 1 أكتوبر 2025، وعن إنهاء عقد بتاريخ 30 سبتمبر 2025. Stephen Connelly, Ph.D. ترقّى إلى رئيس مجلس الإدارة مع الاحتفاظ بدوره كمدير علمي رئيسي (CSO). Daniel M. Bradbury انتقل من رئيس المجلس التنفيذي إلى رئيس مجلس الإدارة، و< b>Bruce Steel يظل المدير التنفيذي وعضو المجلس. قدم كلا من Stephen Connelly و Bala Manian استقالتهما من المجلس، مع الإشارة إلى أنها لا ترتبط بأي خلاف مع الشركة. Separately, اتفقت Equillium وBiocon على إنهاء تعاونهما وترتيبات الترخيص المتعلقة بـ itolizumab.
ركز تعليق الشركة على توجيه مسارها نحو تعزيز خط الإنتاج EQ504 وإدخاله في العيادة وتحسين كفاءة رأس المال.
Equillium (纳斯达克: EQ) 宣布自2025年10月1日起生效的领导力与公司治理更新，以及2025年9月30日的合同终止。Stephen Connelly, Ph.D. 被任命为总裁，同时保留其首席科学官（CSO）职务。Daniel M. Bradbury 由执行董事长改任董事长，Bruce Steel 仍为CEO并且是董事会成员。Stephen Connelly 与 Bala Manian 均向董事会提交了辞呈，表示并非因与公司存在任何分歧而辞职。另据消息，Equillium 与 Biocon 同意终止双方关于 itolizumab 的合作及许可安排。
公司评论强调将管线聚焦于推动 EQ504 进入临床阶段并提升资金利用效率。
- Promotion of Dr Stephen Connelly to President effective October 1, 2025
- Daniel M. Bradbury appointed Chairman of the Board
- CEO Bruce Steel remains in place, preserving executive continuity
- Two board members resigned from the Board effective October 1, 2025
- Termination of collaboration with Biocon on September 30, 2025 ends itolizumab partnership
Insights
Board reshuffle and termination of the Biocon itolizumab collaboration accompany a stated clinical push for EQ504.
The company refocused its leadership and pipeline by promoting Stephen Connelly, Ph.D. to President while he remains Chief Scientific Officer, with Bruce Steel continuing as CEO and Daniel M. Bradbury as Board Chair; two directors resigned and the Biocon collaboration and related agreements for itolizumab were terminated effective
The business mechanism is a tightened governance structure paired with an explicit strategic pivot toward advancing EQ504 into the clinic; management frames these moves as intended to improve capital efficiency and execution.
Key dependencies and risks include the pace and outcome of the planned clinical advance for EQ504, the company’s ability to realize the cited capital efficiencies after ending the itolizumab collaboration, and any follow-on changes to the Board or senior team after the resignations on or around
Concrete items to watch are formal clinical entry milestones for EQ504 (IND/first-in-human filings or trial start), any new partnerships or financing to replace the terminated Biocon collaboration, and further Board composition updates; monitor these developments beginning immediately after
LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced changes to its Board of Directors (BoD) and senior leadership, and other corporate updates.
“The updates we announced today mark an important and timely step as we sharpen our therapeutic pipeline focus on advancing EQ504, our novel aryl hydrocarbon receptor (AhR) modulator, into the clinic to treat severe inflammatory diseases,” said Bruce Steel, Chief Executive Officer at Equillium. “These changes are intended to strengthen our ability to execute with enhanced capital efficiency to bring meaningful new therapies to patients in need. We are very pleased to promote Dr. Stephen Connelly to President, as his scientific and organizational leadership will continue to impact our success into the future. We would also like to sincerely thank Dr. Bala Manian for his service to the company since its inception; his thoughtfulness and insights were always constructive and welcomed by the Board.”
Recent Corporate Updates:
Changes to Corporate Governance Effective October 1, 2025
- Stephen Connelly, Ph.D. has been promoted to President, in addition to his current role as Chief Scientific Officer, of the Company.
- Stephen Connelly, Ph.D. and Bala Manian, Ph.D. tendered their resignations from the BoD; such resignations were not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
- Daniel M. Bradbury transitioned from Executive Chairman of the Company to Chairman of the BoD.
- Bruce Steel remains the Company’s Chief Executive Officer and a member of the BoD.
Termination of Biocon Agreement
- As previously announced, Equillium had no further intention to continue development of itolizumab, therefore on September 30, 2025, Biocon and Equillium entered into an agreement to terminate their collaboration and license agreement and other agreements relating to itolizumab.
About EQ504
EQ504 is an investigational potent and selective aryl hydrocarbon receptor (AhR) modulator designed with a multi-modal, non-immunosuppressive mechanism of action to be complementary to other inflammation and immunology agents. AhR is critical to barrier organ tissue physiology and immunology, maintaining barrier function and promoting tissue repair and regeneration, while regulating resident immune cells with anti-inflammatory responses. EQ504’s preclinical properties provide the potential for targeted, local delivery via enteric coating for the treatment of ulcerative colitis and pouchitis or inhaled formulations for the treatment of inflammatory lung diseases.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders. The Company’s pipeline consists of novel immunomodulatory assets and a product platform targeting immuno-inflammatory pathways.
For more information, visit www.equilliumbio.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future”, “potential” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements include, but are not limited to, the Company’s plans and timing related to the development of EQ504, the potential benefits of EQ504, and the anticipated capital efficiency resulting from the announced changes. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; risks related to performing clinical and pre-clinical studies; whether the results from clinical and pre-clinical studies will validate and support the safety and efficacy of EQ504; changes in the competitive landscape; and changes in Equillium’s strategic plans. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in Equillium's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website and on Equillium’s website under the heading “Investors.” Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investor Contact
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
FAQ
What leadership changes did Equillium (EQ) announce on October 6, 2025?
When did Equillium (EQ) terminate its Biocon collaboration related to itolizumab?
How does the Equillium announcement affect EQ504 development plans?
Who remains in Equillium executive leadership after the October 2025 changes?
Did Equillium say the board resignations were due to disagreements?
When did the leadership and governance changes at Equillium become effective?
